IBDEI1ZV ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33841,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,33841,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,33842,0)
 ;;=C94.41^^131^1680^16
 ;;^UTILITY(U,$J,358.3,33842,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33842,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,33842,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,33842,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,33843,0)
 ;;=D62.^^131^1680^18
 ;;^UTILITY(U,$J,358.3,33843,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33843,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,33843,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,33843,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,33844,0)
 ;;=C92.41^^131^1680^19
 ;;^UTILITY(U,$J,358.3,33844,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33844,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,33844,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,33844,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,33845,0)
 ;;=C92.40^^131^1680^20
 ;;^UTILITY(U,$J,358.3,33845,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33845,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,33845,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,33845,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,33846,0)
 ;;=D56.0^^131^1680^21
 ;;^UTILITY(U,$J,358.3,33846,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33846,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,33846,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,33846,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,33847,0)
 ;;=D63.1^^131^1680^23
 ;;^UTILITY(U,$J,358.3,33847,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33847,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,33847,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,33847,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,33848,0)
 ;;=D63.0^^131^1680^24
 ;;^UTILITY(U,$J,358.3,33848,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33848,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,33848,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,33848,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,33849,0)
 ;;=D63.8^^131^1680^22
 ;;^UTILITY(U,$J,358.3,33849,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33849,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,33849,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,33849,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,33850,0)
 ;;=C22.3^^131^1680^26
 ;;^UTILITY(U,$J,358.3,33850,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33850,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,33850,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,33850,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,33851,0)
 ;;=D61.9^^131^1680^27
 ;;^UTILITY(U,$J,358.3,33851,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33851,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,33851,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,33851,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,33852,0)
 ;;=D56.1^^131^1680^29
 ;;^UTILITY(U,$J,358.3,33852,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33852,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,33852,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,33852,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,33853,0)
 ;;=C83.79^^131^1680^31
 ;;^UTILITY(U,$J,358.3,33853,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33853,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,33853,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,33853,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,33854,0)
 ;;=C83.70^^131^1680^32
 ;;^UTILITY(U,$J,358.3,33854,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33854,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
